Pediatric Praziquantel Consortium: Taking the next step towards access with continued support from the GHIT Fund
13 MAY 2019
The fourth consecutive grant of 4.1 Mio USD from the GHIT Fund provides further support to the Pediatric Praziquantel Formulation Program led by our company for the development, registration and access of a pediatric orally dispersible tablet for preschoolers infected with schistosomiasis.
Despite schistosomiasis being one of the most prevalent parasitic diseases worldwide, preschool-age children are currently left untreated in public health programs due to the lack of a suitable pediatric formulation. With the support of the GHIT Fund, the Pediatric Praziquantel Consortium aims to meet this medical need. With this fourth grant, the GHIT Fund reaffirms its confidence in the Consortium’s program led by our company, through its Global Health Institute.